Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

EClinicalMedicine · 2025 · PMC12554205 · PMID 41146927

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Four hours after APG-2449 administration on Days 1 and 28, pFAK levels in PBMCs showed a trend toward an overall decrease.

also in 53,322 other papers

a positive trendno p-value reported

The exposure-response analysis showed a positive trend, with a higher systemic exposure being significantly associated with greater probabilities of ORR and grade ≥ 3 TRAEs.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.